insulin like growth factor binding protein 1Genealiases: AFBP · IBP1 · IGF-BP25 · PP12 · hIGFBP-1
Q-omics provides the consensus-scored IGFBP1 profile across patient tissues and cancer cell-line models. IGFBP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, IGFBP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, IGFBP1 RNA expression shows 10,315 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, HNSC, and TGCT as cancer lineages where IGFBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGFBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGFBP1 survival associations across molecular data types. IGFBP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGFBP1 RNA expression–survival associations across cancer types. High IGFBP1 expression shows unfavorable associations in STAD, LUAD, ESCA, KIRC and MESO, but favorable associations in SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for IGFBP1 RNA expression.
This table summarizes IGFBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IGFBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGFBP1 shows lower tumor expression in UCEC, BRCA and LIHC and higher tumor expression in HNSC, KIRC and COAD. The HNSC box plot shows higher IGFBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.163, t-test p < 0.001).
This table shows molecular features associated with IGFBP1 in patient tissues and cancer cell lines. In patient samples, IGFBP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IGFBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
